Open an account

Veru

VERU · NASDAQ

$2.38+$0.07 (+3.03%)TodayMarket closed ·
Prev close $2.31

About VERU

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. The company is headquartered in Miami, Florida and currently employs 20 full-time employees. Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.

Employees
20
Headquarters
Miami, Florida
Listed
Jul 19, 1990
Sector
Health Care
Industry
Pharmaceuticals
Website
verupharma.com

VERU key statistics

Market cap
39.22M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
224.24K
Volume
89.89K
Open price
$2.31
High today
$2.40
Low today
$2.31
52 Week high
$7.33
52 Week low
$2.05

Veru (VERU) at a glance

As of Oct 20, 2026, Veru (VERU) shares are priced at $2.38, giving the company a market cap of 39.22M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.31 and $2.40. The current price is 3.0% above the day's low and 0.8% below its high.

Volume so far is 89.89K shares, below the average of 224.24K shares a day.

Over the past year Veru has ranged from $2.05 to $7.33, and now sits 6% of the way up that range.

Veru met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q3 FY26 it reported -$0.30 per share against an estimate of -$0.3264.

The average analyst price target is $24.99, 950.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $24.99
Low
$24.24
Now
$2.38
High
$26.25

VERU earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 38.1% on average.

  1. Q4 FY24: reported -$0.60 per share against an estimate of -$0.7548
  2. Q1 FY25: reported -$0.60 per share against an estimate of -$0.7752
  3. Q2 FY25: reported -$0.50 per share against an estimate of -$0.612
  4. Q3 FY25: reported -$0.50 per share against an estimate of -$0.544
  5. Q4 FY25: reported $0.10 per share against an estimate of -$0.4335
  6. Q1 FY26: reported -$0.26 per share against an estimate of -$0.4794
  7. Q2 FY26: reported -$0.12 per share against an estimate of -$0.2907
  8. Q3 FY26: reported -$0.30 per share against an estimate of -$0.3264

VERU news

  • A Look Ahead: Veru's Earnings Forecast

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Vandana Singh

    Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

  • Press releaseBusiness Wire

    Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology

  • A Look Ahead: Veru's Earnings Forecast

  • Vandana Singh

    Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

  • Earnings Scheduled For May 8, 2025

  • A Peek at Veru's Future Earnings

Similar companies

Companies in the same industry as Veru

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.